Cecilia Perret
Overview
Explore the profile of Cecilia Perret including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
286
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rivera-Perez D, Mendez C, Diethelm-Varela B, Melo-Gonzalez F, Vazquez Y, Meng X, et al.
Front Immunol
. 2024 May;
15:1372193.
PMID: 38812507
Background: Vaccine effectiveness against SARS-CoV-2 infection has been somewhat limited due to the widespread dissemination of the Omicron variant, its subvariants, and the immune response dynamics of the naturally infected...
2.
Weitzel T, Brown A, Libman M, Perret C, Huits R, Chen L, et al.
J Travel Med
. 2024 Jan;
31(4).
PMID: 38245913
Background: Prolonged diarrhoea is common amongst returning travellers and is often caused by intestinal protozoa. However, the epidemiology of travel-associated illness caused by protozoal pathogens is not well described. Methods:...
3.
Le Corre N, Abarca K, Astudillo P, Potin M, Lopez S, Goldsack M, et al.
Vaccines (Basel)
. 2023 Oct;
11(10).
PMID: 37896930
During the COVID-19 pandemic, the importance of vaccinating children against SARS-CoV-2 was rapidly established. This study describes the safety of CoronaVac in children and adolescents between 3- and 17-years-old in...
4.
Castro-Rodriguez J, Fish E, Montgomery S, Kollmann T, Iturriaga C, Shannon C, et al.
EClinicalMedicine
. 2023 Aug;
62:102082.
PMID: 37538539
Background: Accumulating evidence indicates that an early, robust type 1 interferon (IFN) response to SARS-CoV-2 is important in determining COVID-19 outcomes, with an inadequate IFN response associated with disease severity....
5.
6.
Perez C, Ormazabal I, Perez-Valenzuela J, Araya A, Medina R, Perret C
Front Pediatr
. 2022 Dec;
10:957273.
PMID: 36523397
Background: SARS-CoV-2 is an emerging virus that has mainly affected adults; hence, most clinical information has been derived from that population. Most pediatric cases are mild and with nonspecific symptoms...
7.
Soto J, Melo-Gonzalez F, Gutierrez-Vera C, Schultz B, Berrios-Rojas R, Rivera-Perez D, et al.
mBio
. 2022 Nov;
13(6):e0131122.
PMID: 36383021
Multiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been evaluated in clinical trials. However, trials addressing the immune response in the pediatric population are scarce. The inactivated...
8.
Rodriguez-Morales A, Lopardo G, Verbanaz S, Orduna T, Lloveras S, Azenas-Burgoa J, et al.
Lancet Reg Health Am
. 2022 Jul;
13:100318.
PMID: 35813461
No abstract available.
9.
Rodriguez-Morales A, Bonilla-Aldana D, Suarez J, Franco-Paredes C, Forero-Pena D, Mattar S, et al.
Travel Med Infect Dis
. 2021 Nov;
44:102192.
PMID: 34751150
No abstract available.
10.
Iturriaga C, Eiffler N, Aniba R, Ben-Othman R, Perez-Mateluna G, Meyer J, et al.
BMC Infect Dis
. 2021 Aug;
21(1):814.
PMID: 34388972
Background: SARS-CoV-2 infection rapidly spreads in populations due to the high rates of community transmission. Interrupting the shedding of SARS-CoV-2 may reduce the incidence of Coronavirus Disease 19 (COVID-19). Herein...